Share This Article:

Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced urothelial carcinoma

DOI: 10.4236/mc.2013.21001    3,203 Downloads   9,283 Views   Citations

ABSTRACT

Background: Methotrexate, vinblastine, doxorubicin, and cisplatin regimen, and gemcitabine and cisplatin regimen are widely used for advanced or metastatic urothelial carcinomas (UCs). However, a standard treatment for patients who fail these firstline chemotherapies is unavailable. We examined the efficacy and safety of secondline paclitaxel, gemcitabine, and cisplatin (PCG) chemotherapy in Japanese patients. Methods: Between 2004 and 2010, 25 patients with metastatic UCs who failed to respond to platinumbased regimens were treated with PCG. They received intravenous paclitaxel (60 mg/m2) and gemcitabine (1000 mg/m2) on days 1 and 8, and cisplatin (70 mg/m2) on day 2 of every 21 day course. We retrospectively collected patients’ clinical and pathological data and evaluated adverse effects and survivals. Results: Patients underwent 95 PCG cycles in all (average, 3.8 cycles per patient). One patient (4%) achieved complete response, 5 (20%) showed partial response, 8 (42%) had disease stabilization, and 5 (26%) had disease progression. Median overall survival was 8.5 months. Neutropenia and thrombocytopenia of grade ≥ 3 were observed in 68% and 56% of patients, respectively. No treatment related death occurred. Multivariate analysis revealed that hemoglobin levels < 10 g/dL and estimated glomerular filtration rate < 60 mL/(min1.73 m2) were significant risk factors for overall survival. Conclusion: PCG chemotherapy in the secondline setting potentially contributed to good prognosis in selected patients with relatively significant but tolerable toxicity.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Takeshita, H., Chiba, K., Kitayama, S., Moriyama, S., Omura, R. and Noro, A. (2013) Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced urothelial carcinoma. Modern Chemotherapy, 2, 1-7. doi: 10.4236/mc.2013.21001.

References

[1] Loehrer, P.J., Sr, Einhorn, L.H., Elson, P.J., Crawford, E.D., Kuebler, P., Tannock, I., et al. (1992) A randomized comparison of cisplatin alone or in combination with me- thotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group stu- dy. Journal of Clinical Oncology, 10, 1066-1073.
[2] Saxman, S.B., Propert K.J., Einhorn, L.H., Crawford, E.D., Tannock, I., Raghavan, D., et al. (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial car- cinoma: a cooperative group study. Journal of Clinical Oncology, 15, 2564-2569.
[3] von der Maase, H., Sengelov, L., Roberts, J.T., Ricci, S., Dogliotti, L., Oliver, T., et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Cli- nical Oncology, 23, 4602-4608. doi:10.1200/JCO.2005.07.757
[4] Sternberg, C.N., Calabrò, F., Pizzocaro, G., Marini, L., Schnetzer, S., Sella, A. (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have re- ceived prior cisplatin-based therapy. Cancer, 92, 2993- 2998. doi:10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2
[5] Fechner, G., Siener, R., Reimann, M., Kobalz, L., Albers, P. (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with tran- sitional cell carcinoma (AUO Trial AB 20/99). The In- ternational Journal of Clinical Practice, 60, 27-31. doi:10.1111/j.1742-1241.2005.00663.x
[6] Matsumoto, K., Irie, A., Satoh, T., Okazaki, M., Iwamura, M., Baba, S. (2007) Gemcitabine and paclitaxel chemo- therapy as a second-line treatment for advanced or me- tastatic urothelial carcinoma. International Journal of Urology, 14, 1000-1004.
[7] Kanai, K., Kikuchi, E., Ohigashi, T., Miyajima, A., Na- kagawa, K., Nakashima, J., et al. (2008) Gemcitabine and paclitaxel chemotherapy for advanced urothelial carci- noma in patients who have received prior cisplatin-based chemotherapy. International Journal of Clinical Onco- logy, 13, 510-514. doi:10.1007/s10147-008-0779-x
[8] Culine, S., Theodore, C., De Santis, M., Bui, B., Demkow, T., Lorenz, J., et al. (2006) A phase II study of vinflunine in bladder cancer patients pro?gressing after first-line pla- tinum-containing regimen. British Journal of Cancer, 94, 1395-1401. doi:10.1038/sj.bjc.6603118
[9] Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., et al. (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Journal of Clinical Oncology, 27, 4454-4461. doi:10.1200/JCO.2008.20.5534
[10] Bellmunt, J., Guillem, V., Paz-Ares, L., González-Larriba, J.L., Carles, J., Batiste-Alentorn, E., et al. (2000) Phase I-II study of paclitaxel, cisplatin, and gemcitabine in ad- vanced transitional-cell carcinoma of the urothelium. Journal of Clinical Oncology, 18, 3247-3255.
[11] Bellmunt, J., von der Maase, H., Mead, G.M., Skoneczna, I., De Santis, M., Daugaard, G., et al. (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcit- abine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Jour- nal of Clinical Oncology, 30, 1107-1113.
[12] Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R. (1987) A new method of classifying prognostic comor- bidity in longitudinal studies: Development and valida- tion. Journal of Chronic Diseases, 40, 373-383.
[13] Romano, P.S., Roos, L.L., Jollis, J.G. (1993) Adapting a clinical comorbidity index for use with ICD-9-CM ad- ministrative data: differing perspectives. Journal of Clini- cal Epidemiology, 46, 1075-1079.
[14] Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. American Journal of Kidney Diseases, 53, 982-992. doi:10.1053/j.ajkd.2008.12.034
[15] Therasse, P., Arbucl, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute. 92, 205-216.
[16] Fukui, I., Yonese, J., Tsukamoto, T., Yoshida, T., Kim, T., Tohma, T., et al. (2001) Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for me- mtastatic urothelial cancer. Cancer Chemotherapy and Pharmacology, 48, 88-93.
[17] Tatokoro, M., Kawakami, S., Yonese, J., Fujii, Y., Okubo, Y., Yamamoto, S., et al. (2008) Preliminary report of mul- timodal treatment with ifosfamide, 5-fluorouracil, eto- poside and cisplatin (IFEP chemotherapy) against metas- tatic adenocarcinoma of the urachus. International Jour- nal of Urology, 15, 851-853. doi:10.1111/j.1442-2042.2008.02113.x
[18] Bellmunt, J., Albanell, J., Paz-Ares, L., Climent, M.A., González-Larriba, J.L., Carles, J., et al. (2002) Pretreat- ment prognostic factors for survival in patients with- advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer, 95, 751-757. doi:10.1002/cncr.10762
[19] Bellmunt, J., Choueiri, T.K., Fougeray, R., Schutz, F.A., Salhi, Y., Winquist, E., et al. (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with plati- num-containing regimens. Journal of Clinical Oncology, 28, 1850-1855. doi:10.1200/JCO.2009.25.4599
[20] Saito, K., Urakami, S., Komai, Y., Yasuda, Y., Kubo, Y., Kitsukawa, S., et al. (2012) Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chem?otherapy with gemcitabine, etoposide and cisplatin. BJU International, 110, 1478-1484. doi:10.1111/j.1464-410X.2012.11153.x
[21] Thrasher, J.B., Frazier, H.A., Robertson, J.E., Dodge, R.K., Paulson, D.F. (1994) Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell car- cinoma of the bladder and prostate. Cancer, 73, 1708- 1715. doi:10.1002/1097-0142(19940315)73:6<1708::AID-CNCR2820730626>3.0.CO;2-J
[22] Orita, Y., Gejyo, F., Sakatsume, M., Shiigai, T., Maeda, Y., Imai, E., et al. (2005) Estimation of glomerular filtration rate by inulin clearance: comparison with creatinine clea- rance (article in Japanese). Nihon Jinzo Gakkai Shi, 47, 804-812.
[23] Paz-Ares, L.G., Solsona, E., Esteban, E., Saez, A., Gon- zalez-Larriba, J., Anton, A., et al. (2010) Randomized phase III trial comparing adjuvant paclitaxel/gemcita- bine/cisplatin (PGC) to observation in patients with re- sected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. Journal of Clinical Oncology, 28, 18s.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.